ARTICLE | Company News
GlobeImmune, Celgene deal
August 10, 2015 7:00 AM UTC
Celgene exercised its option under an 2009 deal and received exclusive, worldwide rights to oncology candidate GI-6207 from GlobeImmune. GlobeImmune will receive a $1.9 million option exercise fee an...